While Peter Bach and Mark Trusheim argue for throwing in the proverbial towel on biosimilars, Adam Fein suggests the two are surrendering too early.
“This strategy [price regulation] may save some money in the short run, but it risks destroying a market that is finally beginning to fulfill its promise,” Fein writes.
Fein in his defense of biosimilars points to data he says supports hits outlook.
” … Adoption rates for the most recently launched products — biosimilars of Neulasta and Epogen — are growing quickly, and the prices are declining,” he writes. “These products are penetrating the market much faster than the biosimilars of Remicade did. Substitution rates for the upcoming wave of oncology biosimilars will likely penetrate even faster.”
To read Fein’s post, click here.
Click here to read Bach and Trusheim’s article in the Wall Street Journal. (Paid subscription required)